Cargando…
The economic burden of TNFα inhibitors and other biologic treatments in Norway
OBJECTIVE: Costly biologic therapies have improved function and quality of life for patients suffering from rheumatic and inflammatory bowel diseases. In this survey, we aimed to document and analyze the costs. METHODS: In 2008, the total costs of tumor necrosis factor alpha inhibitors and other bio...
Autores principales: | Norum, Jan, Koldingsnes, Wenche, Aanes, Torfinn, Antonsen, Margaret Aarag, Florholmen, Jon, Kondo, Masahide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169971/ https://www.ncbi.nlm.nih.gov/pubmed/21935335 http://dx.doi.org/10.2147/CEOR.S15988 |
Ejemplares similares
-
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
por: Norum, Jan, et al.
Publicado: (2017) -
Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?
por: Cui, Guanglin, et al.
Publicado: (2022) -
Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis
por: Besada, Emilio, et al.
Publicado: (2015) -
Is the Disease Burden from COPD in Norway Falling off? A Study of Time Trends in Three Different Data Sources
por: Melbye, Hasse, et al.
Publicado: (2020) -
Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers
por: Cui, Guanglin, et al.
Publicado: (2021)